Pharmaceutical development scientist turned entrepreneur with more than twenty years of experience in drug development. Trained in Physical Chemistry at McGill University, I have expertise in early-stage drug development, from discovery to phase II, but also contributed significantly to one approved NDA, providing exposure to the expectations of regulators. I have worked on a variety of drug products, from small molecules to peptides, and participated in the successful filing and execution of clinical trials while operating in virtual pharma company environments. At Inversago, led three financing rounds totaling more than US$110M since 2018. With an experienced management team and extensive network of experts, Inversago rapidly brought its first-in-class peripheral CB1 blockers to the clinic and is now conducting clinical proof of concept studies on their way to exploit their full medical potential. Pharmaceutical development scientist turned entrepreneur with more than twenty years of experience in drug development. Trained in Physical Chemistry at McGill University, I have expertise in early-stage drug development, from discovery to phase II, but also contributed significantly to one approved NDA, providing exposure to the expectations of regulators. I have worked on a variety of drug products, from small molecules to peptides, and participated in the successful filing and execution of clinical trials while operating in virtual pharma company environments. At Inversago, led three financing rounds totaling more than US$110M since 2018. With an experienced management team and extensive network of experts, Inversago rapidly brought its first-in-class peripheral CB1 blockers to the clinic and is now conducting clinical proof of concept studies on their way to exploit their full medical potential.

• 

  CEO & President at Inversago Pharma in Noa Therapeutics

  Breaking free from convention, Noa aims to revolutionize treatment options for complex inflammatory skin diseases.